Enlivex Secures Japanese Patent for Osteoarthritis Therapy
Company Announcements

Enlivex Secures Japanese Patent for Osteoarthritis Therapy

Enlivex (ENLV) has released an update.

Enlivex Therapeutics announced a major milestone as the Japanese Patent Office granted a notice of allowance for a patent covering its Allocetra™ treatment for osteoarthritis, expected to be formally issued by mid-2025. This patent, extending protection through 2040, strengthens Enlivex’s intellectual property position and highlights its strategic focus on developing innovative therapies for unmet medical needs in key global markets.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEnlivex Therapeutics Reschedules Annual Shareholders Meeting
TheFlyEnlivex Therapeutics receives notice of allowance from Japanese Patent Office
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App